UNSPSC 51202302: Briakinumab

This classification denotes a monoclonal antibody with the molecular formula C6376H9874N1722O1992S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 978I8M0P8X, more generally known as briakinumab. European Medicines Agency schedules briakinumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31454. The term BRIAKINUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 24, No. 1, 2010 list 63.

As of Q4 2014, BRIAKINUMAB remains US FDA's Preferred Term for this commodity.

UNSPSC 51202302 Briakinumab is a Commodity code that in recent state and local procurement shows little activity aligned with its nominal scope. The three recent opportunities tagged under this code—a Seminole County naloxone and drug deactivation systems purchase, a Texas HHS direct-to-manufacturer pharmacy initiative RFI, and a Minnesota multistate cooperative purchasing RFP for generic pharmaceuticals and OTC products—do not represent briakinumab procurement. Briakinumab is a monoclonal antibody used to treat inflammatory conditions; the opportunities instead span emergency-response pharmaceuticals, pharmacy benefit program innovation, and multi-source generic and OTC inventory. The issuing bodies span county health departments, state HHS agencies, and multi-state cooperative purchasing alliances, but these opportunities do not reflect a coherent buying pattern under the code's nominal classification.

Recent activity appears concentrated in Florida, Texas, and Minnesota, but the geographic scope and issuing-body mix are not meaningful signals for briakinumab demand. Seminole County's IFB (due July 26, 2023) solicited naloxone and drug deactivation systems through competitive sealed bidding with quarterly deliveries and E-Verify compliance required. Texas HHS issued an RFI (due April 3, 2026) to explore direct-to-manufacturer pharmacy contracting models outside traditional PBM and GPO channels. Minnesota's MMCAP posted an RFP (due March 26, 2026) seeking generic pharmaceuticals and OTC products through authorized wholesalers with cGMP and DSCSA certification required. None of these opportunities align with briakinumab's therapeutic indication or procurement pattern. The code appears misapplied or dormant for its stated commodity; vendors pursuing biologics or inflammatory-disease therapeutics in state and local markets should not rely on this code as a reliable sourcing signal.